Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04891640 · ClinicalTrials.gov registry record · NA

Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis

A NA study of Juvenile Spondyloarthritis, sponsored by Children's Hospital of Philadelphia.

Active
Registry status
NA
Development phase
164
Enrollment target
20
Study locations

NCT04891640: Active NA study of Juvenile Spondyloarthritis, sponsored by Children's Hospital of Philadelphia.

NCT04891640 is a NA study of Juvenile Spondyloarthritis that is active but no longer recruiting, run by Children's Hospital of Philadelphia. The registered enrollment target is 164 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04891640, a NA study of Juvenile Spondyloarthritis, is active but no longer recruiting, sponsored by Children's Hospital of Philadelphia.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
164 participants
Enrollment target
20
Study locations

Study Summary

This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 29 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.

Primary Outcome

JSpA flare is defined as clinically meaningful worsening in ≥3 of the following: caregiver/patient assessment of well-being, physician assessment of disease activity, caregiver/patient assessment of pain, physical function, and active joint count. Meaningful change for well-being, disease activity, and pain are an increase of ≥2 on visual analogue scale (range 0-10 with higher scores indicating poorer well-being, higher disease activity, and higher magnitude of pain). Meaningful change in functi

Conditions Studied

Interventions

  • OTHER Standard TNFi Therapy
  • OTHER TNFi fixed longer dosing intervals
  • OTHER Stop TNFi treatment

Study Locations (20)

California

  • Children's Hospital Los Angeles - Los Angeles
  • Stanford University - Palo Alto

Missouri

  • Children's Mercy Hospital - Kansas City
  • St. Louis Children's Hospital - St Louis

New York

  • Hospital for Special Surgery - New York
  • Cohen Children's Medical Center - Queens

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • Phoenix Children's - Phoenix

Colorado

  • Children's Hospital of Colorado - Aurora

Delaware

  • Nemours Children's Hospital - Wilmington

District of Columbia

  • Children's National Health System - Washington D.C.

Trial Details

FieldValue
Enrollment Target 164 participants
Start Date 2021-11-11
Est. Completion 2026-07-01
Phase NA
Children's Hospital of Philadelphia

431 total trials

What the registry record for NCT04891640 still lists

NCT04891640 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Juvenile Spondyloarthritis appearing as the primary indexed condition, and to 3 interventions - of which Standard TNFi Therapy is the first listed.

NCT04891640 names 20 study sites across 17 states, led by California, Missouri, New York.

Frequently Asked Questions

What is clinical trial NCT04891640 about?

NCT04891640 is a clinical study titled "Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis". This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 29 participating pediatric healthcare systems. This op...

What is the current status of trial NCT04891640?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 164 participants. The study started on 2021-11-11. Estimated completion is 2026-07-01.

What conditions does trial NCT04891640 study?

This clinical trial studies the following conditions: Juvenile Spondyloarthritis.

What interventions are being tested in trial NCT04891640?

The interventions under investigation include: Standard TNFi Therapy (OTHER), TNFi fixed longer dosing intervals (OTHER), Stop TNFi treatment (OTHER).

Who is sponsoring clinical trial NCT04891640?

This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04891640 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT04891640's enrollment target sits among peer trials

164 626th of 2000 higher than 1,374 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04891289 · 164 participants · Phase 2

    Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

  • NCT04893226 · 164 participants · NA

    Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women

  • NCT05270213 · 164 participants · Phase 1

    Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

  • NCT05543681 · 164 participants · Phase 2

    Clinical Trial on Agitation in Alzheimer's Dementia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04891640, the US trial registry maintained by the National Library of Medicine. NCT04891640 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.